Medtronic has received an expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter, allowing treatment of ventricular arrhythmias. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, underscoring its potential clinical impact. This broader regulatory clearance could strengthen Medtronic's position in cardiac arrhythmia care across international markets, though it represents a step in a longer commercialization path rather than an immediate shift in the overall business mix.
Medtronic PLCExpanded CE Mark approval for Affera system in ventricular arrhythmias strengthens Medtronic's cardiac arrhythmia position in international markets.
